Jenburkt Pharmaceuticals logo

Jenburkt Pharmaceuticals financials: balance sheet, profit and loss, cash flow

NSE: JENBURPHBSE: 524731Pharmaceuticals & BiotechnologySmall Cap

Jenburkt Pharmaceuticals Limited · Face value ₹10 · Listed Jan 1995
Last close ₹875.95up ₹0.50 (0.06%)

Share price at the NSE close on 28 Oct 2026. Previous close ₹875.45.

28 Oct: open ₹888.90, high ₹888.90, low ₹875.05

52-week range of BSE trades to 27 Oct 2026
₹852.00Low, 23 Oct 2026₹1,321.00High, 31 Oct 2025
Market cap
₹387 Cr1,871st largest listed
P/E
11.78
P/E without one-offs
10.51
P/B
1.96
Dividend yield
2.36%
ROE
17.8%
ROE without one-offs
19.9%
ROCE
19.2%
Debt to equity
0.00
Volume, NSE
1,58792.4% delivered

Jenburkt Pharmaceuticals' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them. It had no borrowings at 31 Mar 2026.

10 years at a glance

₹ crore, years to March.Jenburkt Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
10313Mar 1711517Mar 18123207.5Mar 19119153.4Mar 20109173.7Mar 21124225.8Mar 22137252.4Mar 23142260Mar 24152322.0Mar 25169350Mar 26
Peak revenue ₹169 Cr, year to Mar 2026; lowest ₹103 Cr, year to Mar 2017

Operating and net margin, per cent

  • Operating margin
  • Net margin
26.6%12.5%19.1%20.7%20.4%16.6%18.2%22.0%22.2%23.3%26.6%25.9%13.0%15.0%16.1%12.5%15.1%18.0%18.0%18.3%21.1%20.6%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.7% of operating profit in the first full year.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue169
  2. Materials and goods−32
  3. Employee costs−50
  4. Other expenses−43
  5. Operating profit44
  6. Depreciation−3.1
  7. Other income+10
  8. One-off items−4.0
  9. Finance costs−0.5
  10. Profit before tax47
  11. Tax−12
  12. Net profit35

What the company owns

  • Plant, investments and other assets₹135 Cr
  • Cash and bank₹53 Cr
  • Receivables₹24 Cr
  • Inventory₹14 Cr

What pays for it: net worth and liabilities

  • Net worth₹197 Cr
  • Other liabilities₹21 Cr
  • Owed to suppliers₹8 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Jenburkt Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Filed 23 MayMar 2024Mar 2025Mar 2026Filed 5 MayJun 2026Twelve monthsFiled 6 Aug
Revenue from operations103115123119109124137142152169169
849198998997106109111125128
Materials and goods bought3134363330313330303232
Employee costs2428313732363942465051
Other expenses2929303027293536364345
Operating profit before depreciation2024252020273033404441
Operating margin19.1%20.7%20.4%16.6%18.2%22.0%22.2%23.3%26.6%25.9%24.2%
Materials, % of revenue29.6%29.6%29.6%27.8%27.5%25.4%24.1%21.4%19.6%19.2%19.0%
Employee costs, % of revenue23.5%24.1%25.4%30.7%29.6%29.4%28.4%29.9%30.0%29.6%30.3%
Other expenses, % of revenue27.8%25.5%24.6%24.9%24.7%23.2%25.3%25.3%23.8%25.4%26.4%
Depreciation and amortisation22122222333
Operating profit after depreciation1822241718252831384138
Other income3334455571010
Finance costs00010000000
Profit before one-off items and tax2025272122303335445047
One-off items0–0000000−4−4
Profit before tax2025272122303335444743
78765889121210
Net profit1317201517222526323533
Other comprehensive income––0−221032−2−1
Total comprehensive income––201318242529343331
Net margin13.0%15.0%16.1%12.5%15.1%18.0%18.0%18.3%21.1%20.6%19.5%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Filed 23 MayMar 2024Mar 2025Mar 2026Filed 5 May
778098117122145172197
Share capital55554444
Reserves737594113118141167193
Borrowings73462020
2320182116161923
34444466
Total assets103104120143142165196226
131540676155140131
90908076811105795
Net debt−48−56−53−43−51−79−23−53
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Filed 23 MayMar 2024Mar 2025Mar 2026Filed 5 May
19.59.417.18.127.926.5
25.317.025.316.541.338.3
–−10.7−5.5−16.90.6−4.9
Receivables–−1.0−1.0−17.9−2.6−0.3
Inventories–−2.31.6−0.2−0.3−4.8
Payables–2.5−1.00.21.9−0.1
Other working capital–−9.8−5.01.01.60.3
Tax paid−5.80.0−8.2−8.3−13.4−11.8
Interest paid0.0−7.60.00.00.00.0
Capital spending1.13.12.12.619.713.7
Free cash flow18.36.314.95.68.212.8
−18.8−1.32.6−0.6−17.0−19.5
−0.7−5.5−21.0−7.1−7.6−8.9
Dividends paid0.14.75.56.36.87.9
Shares bought back0.00.014.50.00.00.0
Shares issued0.00.00.00.00.00.0
Net change in cash0.02.5−1.40.53.2−1.8
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.Jenburkt Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Filed 23 MayMar 2024Mar 2025Mar 2026Filed 5 May
Earnings per share₹28.96₹37.50₹43.14₹32.40₹35.96₹48.58₹53.90₹58.86₹72.65₹78.71
Diluted earnings per share₹28.96₹37.50₹43.14₹32.40₹35.96₹48.58₹53.90₹58.86₹72.65₹78.71
Dividend per share₹8.10₹9.00₹10.20₹8.10₹10.20₹12.00₹14.40₹15.30₹18.00₹20.70
Book value per share––₹168.79₹174.32₹214.55₹255.77₹277.32₹328.42₹389.23₹446.47
Dividend payout28.0%24.0%23.6%25.0%28.4%24.7%25.8%26.0%24.8%26.3%
Shareholder yield––––0.1%1.8%6.6%2.1%1.5%1.9%
Market cap at the year end (₹ crore)223284232146183260304304446422

Ratios

Standalone, years to March.Jenburkt Pharmaceuticals PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Filed 23 MayMar 2024Mar 2025Mar 2026Filed 5 May
Revenue growth–11.0%7.0%−3.1%−8.1%13.4%10.3%3.8%6.9%11.2%
Operating profit growth–20.5%4.9%−20.9%0.5%37.4%11.4%9.1%22.0%8.3%
Net profit growth–27.8%15.0%−24.9%11.0%35.1%10.4%5.6%23.4%8.3%
Earnings per share growth–29.5%15.0%−24.9%11.0%35.1%11.0%9.2%23.4%8.3%
––25.6%18.9%18.5%20.7%20.5%19.4%20.2%18.8%
–––−6.7 pts−0.4 pts2.2 pts−0.1 pts−1.1 pts0.8 pts−1.4 pts
From the net margin–––−5.8 pts3.9 pts3.5 pts0.0 pts0.3 pts3.0 pts−0.5 pts
From asset turnover–––−0.7 pts−3.5 pts−0.7 pts0.4 pts−0.8 pts−2.1 pts−0.9 pts
From borrowing–––−0.2 pts−0.8 pts−0.6 pts−0.6 pts−0.7 pts−0.1 pts0.1 pts
Return on capital employed––27.8%20.9%17.4%20.6%22.5%21.2%21.7%20.6%
Cash conversion––––117.9%42.2%69.3%31.3%87.0%76.4%
Interest cover43.854.161.233.237.658.476.6113.783.287.9
Debt to equity––0.100.040.040.050.020.000.010.00
Receivable days––6855474545505053
Inventory days––991209211592103109154
Payable days––66584983677510091
Cash conversion cycle, days––1011179077707859115
Working capital days––5743303437363641
Asset turnover––1.191.150.970.940.960.930.840.80
Assets per rupee of net worth––1.331.311.261.221.191.151.141.14
Sales per rupee of plant––13.0013.3612.8512.4613.3314.2410.518.78
Capital spending to depreciation––––0.561.610.931.097.234.41
Plant being built, % of plant in use––10.5%1.3%4.4%2.1%9.3%12.4%279.1%239.9%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
16.5%
Cash from operations against operating profit
60.6%
Measure10 years5 years3 years
Revenue growth, yearly rate–9.1%7.3%
Profit growth, yearly rate–16.1%12.2%
Return on equity, average–19.9%19.5%
Return on capital employed, average–21.3%21.2%
Operating margin, average21.5%24.0%25.3%
Net margin, average16.8%19.2%20.0%
Asset turnover, average–0.890.85
Cash conversion cycle, days, average–8084
Interest cover, average65.084.094.9
Debt to equity, average–0.020.00

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations89.062.626.5
Cash from investing−35.8−37.1−19.5
Cash from financing−50.1−23.6−8.9
Capital spending41.136.013.7
Dividends paid31.221.07.9
Shares bought back14.50.00.0
Shares issued for cash0.00.00.0
Borrowings raised0.00.00.0
Borrowings repaid0.30.00.0

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––645755
Altman Z-scorePublished threshold 1.81––9.327.288.239.2312.5412.4913.9211.74
Beneish M-scorePublished threshold −1.78––––−0.29−1.73−2.13−1.95−1.49−2.26
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––14.1010.813.4712.0111.7413.10
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.720.470.640.67
Receivables growth less revenue growthOur threshold 0 percentage points–––−19.06−13.40−4.821.2411.00−0.386.23
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––19.66−21.4625.98−20.6710.546.2044.52
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−0.060.120.100.190.39−0.131.01
Assets under construction, years of additionsOur threshold 2 years of additions–––0.070.230.060.370.615.615.84
Effective tax ratePublished threshold 17.16 per cent34.1231.8825.6729.6523.7525.3525.1326.1527.0225.33
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––25.350.102.42−3.55−0.01
A threshold marked as ours has no published figure; it is the line we read the check against.